These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4896 related articles for article (PubMed ID: 2920369)

  • 1. Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of stage II disease.
    Berdeaux DH; Meyskens FL; Parks B; Tong T; Loescher L; Moon TE
    Cancer; 1989 Apr; 63(7):1430-6. PubMed ID: 2920369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).
    Balch CM; Soong SJ; Murad TM; Ingalls AL; Maddox WA
    Ann Surg; 1981 Mar; 193(3):377-88. PubMed ID: 7212800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease.
    Meyskens FL; Berdeaux DH; Parks B; Tong T; Loescher L; Moon TE
    Cancer; 1988 Sep; 62(6):1207-14. PubMed ID: 3409189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
    Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
    Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).
    Balch CM; Soong SJ; Murad TM; Smith JW; Maddox WA; Durant JR
    J Clin Oncol; 1983 Feb; 1(2):126-34. PubMed ID: 6668496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of patients with pathologic stage II cutaneous malignant melanoma.
    Roses DF; Provet JA; Harris MN; Gumport SL; Dubin N
    Ann Surg; 1985 Jan; 201(1):103-7. PubMed ID: 3966826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Long GV; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Kefford RF; Thompson JF; Scolyer RA
    Ann Surg Oncol; 2012 Jun; 19(6):1782-9. PubMed ID: 22350600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in young women with cutaneous melanoma.
    Burton AL; Egger ME; Quillo AR; Stromberg AJ; Hagendoorn L; Scoggins CR; Martin RC; McMasters KM; Callender GG
    Am J Surg; 2014 Jan; 207(1):102-8. PubMed ID: 24330977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
    Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
    Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis.
    Day CL; Mihm MC; Lew RA; Harris MN; Kopf AW; Fitzpatrick TB; Harrist TJ; Golomb FM; Postel A; Hennessey P; Gumport SL; Raker JW; Malt RA; Cosimi AB; Wood WC; Roses DF; Gorstein F; Rigel D; Friedman RJ; Mintzis MM; Sober AJ
    Ann Surg; 1982 Jan; 195(1):35-43. PubMed ID: 7055382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous malignant melanoma in West Yorkshire: II. A prospective study of recurrence and prediction of lymph nodal metastasis.
    Eastwood J; Baker TG
    Br J Cancer; 1984 Jul; 50(1):35-43. PubMed ID: 6743514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging.
    Dodds TJ; Lo S; Jackett L; Nieweg O; Thompson JF; Scolyer RA
    Am J Surg Pathol; 2018 Mar; 42(3):359-366. PubMed ID: 29240580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Outcome and Prognostic Factors for Malignant Skin Melanoma Treated with Radical Surgery.
    Majewski W; Stanienda K; Wicherska K; Ulczok R; Wydmanski J
    Asian Pac J Cancer Prev; 2015; 16(14):5709-14. PubMed ID: 26320440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
    Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
    Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous melanoma: prognosis and treatment results worldwide.
    Balch CM
    Semin Surg Oncol; 1992; 8(6):400-14. PubMed ID: 1439450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage II malignant melanoma: presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients.
    Slingluff CL; Vollmer R; Seigler HF
    J Surg Oncol; 1988 Nov; 39(3):139-47. PubMed ID: 3184950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant melanoma: prognostic indicators.
    Ahmed I
    Mayo Clin Proc; 1997 Apr; 72(4):356-61. PubMed ID: 9121184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
    Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
    Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 245.